AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

New Cryptophycins for ADC and SMDC

Summary
New conjugation of cryptophycins for use in ADC (antibody-drug conjugates) and SMDC (small molecule drug conjugates)
Technology Benefits
The present invention combines new synthetic ways to new Cryptophycin derivatives with alternative conjugation possibilites and pico-molar cytotoxicies, for ADC and SMDC synthesis. It can be linked to selective antibodies, peptides or other ligands which address tumour antigens and may therefore be used for anticancer therapy.
Technology Application
To circumvent such side effects, cryptophycin could be used as payload for drug-conjugates. For treatment of solid tumours ADCs have only little effects, therefore SMDCs have more advantages in relation. To date, there are only few ADCs approved for cancer therapy and higher diversity is desirable to compensate for emerging resistances. In addition, there is also need in the art for novel, highly potent toxins, with no cryptophycin-based ADCs being approved so far.
Detailed Technology Description
Cryptophycins are discussed as potential medicaments against cancer due to their high cytotoxic and cytostatic effect. They target tubulin and block the microtubule formation, leading to high cytotoxicity against many cancer cell lines. Moreover, as they are a weak target for the P-gp efflux pump, the cytotoxicity is only slightly reduced in multidrug-resistant (MDR) cancer cells. Due to these characteristics, several cryptophycin analogues were investigated as chemotherapeutics and cryptophycin-52 was even brought to the clinics. However, these were discontinued in phase II because of neurotoxic side effects and insufficient efficacy. These effects made a direct approach unusable for cancer treatment so far.
Type of Cooperation
Licensing
Application Date
19/02/2021 00:00:00
Application No.
EP 21 158 130.1
Others
No CN patents
ID No.
5817
Country/Region
Germany

For more information, please click Here
Mobile Device